PMID- 24252186
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131122
LR  - 20211021
IS  - 2050-7771 (Print)
IS  - 2050-7771 (Electronic)
IS  - 2050-7771 (Linking)
VI  - 1
IP  - 1
DP  - 2013 Nov 15
TI  - Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin 
      lymphoma.
PG  - 30
LID - 10.1186/2050-7771-1-30 [doi]
AB  - Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
      signaling pathway is extensively explored in cancers. It functions as an 
      important regulator of cell growth, survival and metabolism. Activation of this 
      pathway also predicts poor prognosis in numerous human malignancies. Drugs 
      targeting this signaling pathway have been developed and have shown preliminary 
      clinical activity. Accumulating evidence has highlighted the important role of 
      PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and 
      progression. Therapeutic functions of PI3K inhibitors in NHL have been 
      demonstrated both in vivo and in vitro. This review will summarize recent 
      advances in the activation of PI3K signaling in different types of NHL and the 
      applications of PI3K inhibitors in NHL treatment.
FAU - Fang, Xiaosheng
AU  - Fang X
AD  - Department of Hematology, Shandong Provincial Hospital affiliated to Shandong 
      University, 324 Jingwu Road, Jinan, Shandong 250021, P,R, China. xinw007@126.com.
FAU - Zhou, Xiangxiang
AU  - Zhou X
FAU - Wang, Xin
AU  - Wang X
LA  - eng
PT  - Journal Article
DEP - 20131115
PL  - England
TA  - Biomark Res
JT  - Biomarker research
JID - 101607860
PMC - PMC4177547
EDAT- 2013/11/21 06:00
MHDA- 2013/11/21 06:01
PMCR- 2013/11/15
CRDT- 2013/11/21 06:00
PHST- 2013/09/09 00:00 [received]
PHST- 2013/11/04 00:00 [accepted]
PHST- 2013/11/21 06:00 [entrez]
PHST- 2013/11/21 06:00 [pubmed]
PHST- 2013/11/21 06:01 [medline]
PHST- 2013/11/15 00:00 [pmc-release]
AID - 2050-7771-1-30 [pii]
AID - 10.1186/2050-7771-1-30 [doi]
PST - epublish
SO  - Biomark Res. 2013 Nov 15;1(1):30. doi: 10.1186/2050-7771-1-30.